TG THERAPEUTICS INC. - COMMON STOCK

TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue and 2025 Anticipated Development Milestones

14 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

09 Jan 2025 07:30:00 By Nasdaq GlobeNewswire

TG Therapeutics to Participate in the Evercore HealthCONx Conference

29 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

25 Nov 2024 09:47:54 By NetDania Notify

TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

21 Nov 2024 06:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

14 Nov 2024 09:55:54 By NetDania Notify

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

13 Nov 2024 11:43:19 By NetDania Notify

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

12 Nov 2024 09:50:33 By NetDania Notify

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

11 Nov 2024 09:45:41 By NetDania Notify

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

08 Nov 2024 14:45:51 By NetDania Notify

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

07 Nov 2024 10:01:11 By NetDania Notify

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

06 Nov 2024 09:45:06 By NetDania Notify

TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance

04 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

01 Nov 2024 11:54:23 By NetDania Notify

TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update

01 Nov 2024 08:06:02 By Nasdaq GlobeNewswire

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

18 Sep 2024 09:45:02 By NetDania Notify

New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis

18 Sep 2024 07:15:00 By Nasdaq GlobeNewswire

New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment

18 Sep 2024 07:00:03 By Nasdaq GlobeNewswire

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

17 Sep 2024 12:04:03 By NetDania Notify

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

16 Sep 2024 14:44:05 By NetDania Notify